February 16, 2026 17:00 ET  | Source: Sapu Bioscience, LLC SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) — Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology, and CNS drug delivery. Background on OT-101 OT-101 (TGF-β antisense inhibitor) is a […]

February 10, 2026 07:30 ET  | Source: Helus Pharma This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) —  Helus PharmaTM (“Helus”)

February 10, 2026 00:55 ET  | Source: Royal Philips February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs

February 10, 2026 01:00 ET  | Source: Royal Philips Amsterdam, February 10, 2026 Full year and Q4 highlights Capital Markets Day Roy Jakobs, CEO of Royal Philips:“In 2025, we delivered on our commitments as we scaled better care for more people. We strengthened our company while navigating a dynamic macro-environment. We ended the year with strong order

February 09, 2026 04:00 ET  | Source: Open Health New York and London, Feb. 09, 2026 (GLOBE NEWSWIRE) — OPEN Health today announced senior leadership appointments that reinforce the company’s commitment to disciplined growth, enterprise alignment, and the company’s purpose of strengthening the decisions that shape care. As healthcare grows more complex, life-sciences organizations face

February 04, 2026 01:30 ET  | Source: Curium BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) — Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies’ registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC). 177Lu-PSMA-I&T is a radiotherapeutic agent